Benzodiazepine Deprescribing

Diazepam-equivalent conversion (Table 3.7) + switch guidance

Lorazepam 2 mgdiazepam 20 mg

Equivalence is approximate — These equivalencies are based on clinical experience and so may not be exact — they may need to be individualised based on withdrawal symptoms. There is no pharmacokinetically precise benzodiazepine conversion (unlike opioids or PPIs); published values vary between sources (e.g. lorazepam 1–2 mg per 10 mg diazepam). Switch step-wise, prioritise the patient's reported symptoms, and allow a period of stabilisation (~2 weeks or longer) on the new drug before starting a taper.

  • Switch: Switch step-wise (not abruptly), prioritise the patient’s reported symptoms, and allow ~2 weeks of stabilisation on the new drug before tapering.
  • Hepatic impairment: In significant hepatic impairment prefer lorazepam (no active metabolites, clearance unaffected by liver function); diazepam, clonazepam and chlordiazepoxide accumulate.

Diazepam-equivalent reference — Maudsley Table 3.7

Drug≈ 10 mg diazepamHalf-lifeClass
Alprazolam0.5 mg12–15 hoursbenzodiazepine
Chlordiazepoxide25 mg8–28 hoursbenzodiazepine
Clonazepam0.5 mg20–60 hours (mean 30 hours)benzodiazepine
Clorazepate15 mg18–50 hours (1–8 days)benzodiazepine
Diazepam10 mg24–48 hours (active metabolite up to 100 hours)benzodiazepine
Estazolam1 mg (1–2 mg)10–24 hoursbenzodiazepine
Eszopiclone3 mg6 hoursz-drug
Flurazepam20 mg (15–30 mg)40–114 hoursbenzodiazepine
Lorazepam1 mg12 hoursbenzodiazepine
Lormetazepam1 mg (1–2 mg)10–12 hoursbenzodiazepine
Nitrazepam10 mg24 hoursbenzodiazepine
Oxazepam20 mg6–20 hoursbenzodiazepine
Quazepam20 mg39 hours (active metabolite 73 hours)benzodiazepine
Temazepam20 mg7–11 hours (mean 8 hours)benzodiazepine
Triazolam0.5 mg1.5–5 hoursbenzodiazepine
Zaleplon20 mg1 hourz-drug
Zolpidem20 mg0.7–3.5 hours (mean 2.4 hours)z-drug
Zopiclone15 mg5 hoursz-drug

Diazepam 10 mg is the anchor unit (the omeprazole-unit analog). Lorazepam is a secondary anchor preferred in hepatic impairment. Source: Horowitz & Taylor, The Maudsley Deprescribing Guidelines (2024), Table 3.7. Per-drug hyperbolic taper schedules are coming next.